OBJECTIVE: To examine the efficacy and safety of infliximab combined with methotrexate compared with methotrexate alone in the treatment of ankylosing spondylitis (AS) using MRI and DXA to monitor its impact on bone. METHODS: In this single centre study 42 subjects with active AS were treated withmethotrexate and were randomly assigned, in a ratio of 2:1, to receive five infusions of either 5 mg/kg infliximab or placebo over 30 weeks. The primary outcome was improvement in disease activity as shown by the BASDAI at week 30. MRI was used to assess the effect of treatments on sacroiliac and spinal enthesitis/osteitis and DXA to monitor bone mineral density. RESULTS: Both therapeutic agents were well tolerated with no dropouts due to adverse events. A significantly greater improvement in mean BASDAI score was seen in the infliximab arm at week 10 (p = 0.017) than in the placebo arm, but this was not maintained by week 30 (p = 0.195), 8 weeks after the last infusion, at which stage disease flares were reported by some subjects. MRI showed that the mean number of lesions resolving for each subject from week 0 to week 30 was significantly greater in the combination group than in the methotrexate monotherapy group (p = 0.016). CONCLUSIONS:Infliximab in combination with methotrexate was a safe and efficacious treatment in AS over 6 months and was associated with significant regression in enthesitis/osteitis as determined by MRI. However, disease flares were reported 8 weeks after the last infusion, indicating that addition of methotrexate failed to extend the infliximab dosing interval.
RCT Entities:
OBJECTIVE: To examine the efficacy and safety of infliximab combined with methotrexate compared with methotrexate alone in the treatment of ankylosing spondylitis (AS) using MRI and DXA to monitor its impact on bone. METHODS: In this single centre study 42 subjects with active AS were treated with methotrexate and were randomly assigned, in a ratio of 2:1, to receive five infusions of either 5 mg/kg infliximab or placebo over 30 weeks. The primary outcome was improvement in disease activity as shown by the BASDAI at week 30. MRI was used to assess the effect of treatments on sacroiliac and spinal enthesitis/osteitis and DXA to monitor bone mineral density. RESULTS: Both therapeutic agents were well tolerated with no dropouts due to adverse events. A significantly greater improvement in mean BASDAI score was seen in the infliximab arm at week 10 (p = 0.017) than in the placebo arm, but this was not maintained by week 30 (p = 0.195), 8 weeks after the last infusion, at which stage disease flares were reported by some subjects. MRI showed that the mean number of lesions resolving for each subject from week 0 to week 30 was significantly greater in the combination group than in the methotrexate monotherapy group (p = 0.016). CONCLUSIONS:Infliximab in combination with methotrexate was a safe and efficacious treatment in AS over 6 months and was associated with significant regression in enthesitis/osteitis as determined by MRI. However, disease flares were reported 8 weeks after the last infusion, indicating that addition of methotrexate failed to extend the infliximab dosing interval.
Authors: L C Doward; A Spoorenberg; S A Cook; D Whalley; P S Helliwell; L J Kay; S P McKenna; A Tennant; D van der Heijde; M A Chamberlain Journal: Ann Rheum Dis Date: 2003-01 Impact factor: 19.103
Authors: Leen De Rycke; Elli Kruithof; Nancy Van Damme; Ilse E A Hoffman; Nancy Van den Bossche; Filip Van den Bosch; Eric M Veys; Filip De Keyser Journal: Arthritis Rheum Date: 2003-04
Authors: J Braun; X Baraliakos; W Golder; J Brandt; M Rudwaleit; J Listing; M Bollow; J Sieper; D Van Der Heijde Journal: Arthritis Rheum Date: 2003-04
Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper Journal: Lancet Date: 2002-04-06 Impact factor: 79.321
Authors: Filip Van Den Bosch; Elli Kruithof; Dominique Baeten; Annemie Herssens; Filip de Keyser; Herman Mielants; Eric M Veys Journal: Arthritis Rheum Date: 2002-03
Authors: J Braun; J Brandt; J Listing; A Zink; R Alten; G Burmester; W Golder; E Gromnica-Ihle; H Kellner; M Schneider; H Sörensen; H Zeidler; J Reddig; J Sieper Journal: Arthritis Rheum Date: 2003-08
Authors: J Zochling; D van der Heijde; R Burgos-Vargas; E Collantes; J C Davis; B Dijkmans; M Dougados; P Géher; R D Inman; M A Khan; T K Kvien; M Leirisalo-Repo; I Olivieri; K Pavelka; J Sieper; G Stucki; R D Sturrock; S van der Linden; D Wendling; H Böhm; B J van Royen; J Braun Journal: Ann Rheum Dis Date: 2005-08-26 Impact factor: 19.103
Authors: Anna Rita Giardina; Angelo Ferrante; Francesco Ciccia; Rosalia Impastato; Maria Concetta Miceli; Alfonso Principato; Giovanni Triolo Journal: Rheumatol Int Date: 2009-10-23 Impact factor: 2.631
Authors: Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper Journal: Arthritis Res Ther Date: 2009-08-17 Impact factor: 5.156